Study of Brentuximab Vedotin in Patients With Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma (NCT01909934)
This is a single-arm, open-label, multicenter, phase IV clinical trial to evaluate the efficacy and safety of brentuximab vedotin as a single agent in patients with relapsed or refractory Systemic Anaplastic Large Cell Lymphoma (sALCL).
This trial is sponsored by Millennium Pharmaceuticals. 
- Condition: Anaplastic Large-cell Lymphoma
- Phase: IV
- Estimated Enrollment: 45
- Start: October 2013
- Estimated Completion: May 2020
- Last verified: February 2015
Last Editorial review: July 17, 2016
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.
Copyright © 2015 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.